



18 January 2013

ASX Market Announcements
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000

**Diagnostic Array Systems Pty Ltd – Japanese Patent Granted For
BacTrac™ Diagnostic Test**

Please find attached an operational update from BPH Energy Ltd (**ASX: BPH**) investee company Diagnostic Array Systems Pty Ltd.

Yours sincerely,

A handwritten signature in blue ink, appearing to read "D Ambrosini".

Deborah Ambrosini
Director and Company Secretary



18 January 2013

ASX Market Announcements
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000

Japanese Patent Granted For BacTrac™ Diagnostic Test

Diagnostic Array Systems Pty Ltd ("DAS") is pleased to announce it has been granted a Japanese patent relating to its BacTrac™ System, a diagnostic tool for the identification of multiple respiratory pathogens. The patent entitled 'Method for the Detection and/or identification of a microorganism' is valid until July 2026. The patent describes a method for the simultaneous detection or identification of multiple microorganisms from a single patient sample.

DAS Chairman, Mr David Breeze stated 'We are very pleased to secure DAS' first granted patent relating to the BacTrac™ System. The granting of this patent paves the way for the Company's other pending patent applications. The detection of multiple respiratory pathogens from a single sputum sample is of significant commercial value and the granting of this patent greatly improves DAS' IP offering'.

DAS holds intellectual property for the BacTrac™ System in Australia, Canada, Japan and the United States.

About BacTrac

The BacTrac™ System is a diagnostic test for the detection of respiratory infections (e.g. diagnosis of Pneumonia, Tuberculosis (TB) and Legionella disease). The BacTrac™ System identifies the cause of disease by testing for multiple bacteria in a single sputum sample. The test has important implications for the clinical management of infectious diseases by identifying the specific bacteria responsible for a disease and suggesting the most effective therapy. Utilisation of the novel test is intended to provide more information, more quickly than alternative methods. It has the potential to accelerate therapeutic treatment, lead to a reduction in hospitalisations and help reduce the overuse of antibiotics.

Yours Sincerely,

A handwritten signature in black ink, appearing to read "D. Breeze", with a stylized flourish at the end.

David Breeze
Director

Diagnostic Array Systems Pty Ltd

ACN 103 314 049

PO box 317, North Perth, WA, 6906

14 View Street, North Perth, Western Australia

T: + 61 8 9328 8366 F: +61 8 9328 8733

admin@bphenergy.com.au www.bphenergy.com.au